Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.69 |
| ▸ | F2 | P00734 | 4/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16730410 | 0.98 | F10 (0.65) | F10F2SLC29A1 | |
| SCHEMBL16730337 | 0.94 | F10 (0.65) | F10F2SLC29A1 | |
| SCHEMBL16730302 | 0.93 | F10 (0.80) | F10F2SLC29A1 | |
| SCHEMBL16730368 | 0.93 | F10 (0.72) | F10F2SLC29A1 | |
| SCHEMBL16730480 | 0.92 | F10 (0.69) | F10F2SLC29A1 | |
| SCHEMBL16730522 | 0.91 | F10 (0.59) | F10F2SLC29A1 | |
| SCHEMBL18028114 | 0.91 | F10 (0.59) | F10F2SLC29A1 | |
| SCHEMBL16730374 | 0.90 | F10 (0.66) | F10F2SLC29A1 | |
| SCHEMBL16730272 | 0.90 | F10 (0.76) | F10F2SLC29A1 | |
| SCHEMBL29805035 | 0.90 | F10 (0.76) | F10F2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815833-B2 | Pyridine derivative and medical use thereof | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-14 | — | — | US | disclosed |
| US-9815833-B2 | Pyridine derivative and medical use thereof | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-14 | — | — | US | disclosed |
| EP-3072892-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) | 2016-09-28 | — | — | EP | disclosed |
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Zhejiang Yatai Pharmaceutical Co., Ltd. (CN) | 2016-08-25 | — | — | US | disclosed |
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Zhejiang Yatai Pharmaceutical Co., Ltd. (CN) | 2016-08-25 | — | — | US | disclosed |
| WO-2015070809-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | 成都苑东药业有限公司 | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | PEPD, F2, XDH | F10 35/4885F2 2/4885SLC29A1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.